Jun 08,2015

LabStyle Innovations Late Breaking Poster Presented at American Diabetes Association 75th Scientific Session

LabStyle Innovations Corp. presented a Poster titled, "Performance of Dario Blood Glucose Monitoring System Evaluated in a Clinical Study in Compliance with the New ISO 15197:2013 Standard," at the ADA's 75th Anniversary Scientific Sessions. The poster revealed the results of a 368 patient Diabetes Type 1 and Type 2 study that was performed in the United States. 97.8% of the Dario glucose results fall within + 0.83 mmol/L (15 mg/dL) at glucose concentrations < 5.5 mmol/L (< 100 mg/dL) and 96.49% of the Dario glucose results fall within + 15% at glucose concentrations >5.5 mmol/L (>100 mg/dL).

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Dario Publishes New Research in Peer Reviewed Journal Demonstrating Improved Outcomes by Race Race and Ethnicity

DarioHealth Corp., a leader in the global digital therapeutics (DTx) market, has published new research in the peer-reviewed journal Applied Sciences showing that users with Type 2 diabetes from different racial and ethnic groups had improved outcomes using their digital therapeutics platform. The new research examined retrospective data from 1,000 users with Type 2 diabetes who engaged with Dario’s platform across a 12-month period. The study found no statistical difference in engagement levels and significant improvements in average blood glucose across all groups over a 12-month period.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

Nemaura Medical announces initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the United Kingdom. The initial pilot program recruited 30 individuals that were classified as obese according to their BMI. The first cohort of 10 patients have been enrolled in the program for over 12 weeks. Results from this cohort indicate that these individuals achieved an average weight loss of 3.7 pounds and an average BMI improvement of 0.6 after 10 weeks, with 100% of participants achieving some weight improvement.

CLINICAL STUDY

#cgm

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 30,2023

Study backs digital diabetes program from Vida Health

San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants demonstrated dramatic improvements in glycemic control. It also highlighted an important relationship between the improved management of depression and diabetes. Participants enrolled in Vida’s interactive digital health diabetes management program. The company designed it to enable members to manage both physical and mental health.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 31,2023

Study Results Published Sustained Clinically Significant Improvements in Over 144,000 People with Diabetes Using a LifeScan's Smart Blood Glucose Meter and Mobile App

The real-world data provides insights into improved glycemic metrics among people with diabetes using a Bluetooth connected BGM together with a diabetes management digital app - in this study, patients used the OneTouch Verio Flex® meter and OneTouch Reveal® app. The retrospective analysis showed that, overall, people with diabetes with at least 180 readings within the 180-day timeframe using the OneTouch Reveal® app with the OneTouch Verio Flex® meter experienced better glycemic control, improving glucose readings in range (70-180 mg/dL) by +6.1 percentage points in T1D, and +11.9 percentage points in T2Ds

CLINICAL STUDY

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 02,2023

Postive phase 2 clinical trial results from NovioSense

NovioSense BV, the venture capital-backed clinical stage medical device company, today announced positive data from its NLNSGS2017-02 Phase 2 tear glucose sensor study. The NovioSense Glucose Sensor is a device that, when placed in the lower eyelid, continuously measures glucose levels in the tear fluid of diabetic patients. The results of the six-patient clinical trial are presented in the American Chemical Society Journal Biomacromolecules.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Dec 05,2022

Scientists Develop 12-Hour Method to Predict Diabetes Onset in Patients Using AI

Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence. In findings presented Friday at the NeurIPS conference in New Orleans, Klick scientists revealed how they used machine learning and just 12 hours of data from CGMs to determine whether a patient was prediabetic or diabetic. Jeon said they discovered their 12-hour model showed similar high accuracy to results from the longer intervals, correctly identifying two-thirds of patients with prediabetes, while also showing high accuracy in identifying healthy patients and those with Type 2 diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial

The objective of the study is to assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes.

CLINICAL STUDY

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes

Current studies on continuous glucose monitor (CGM) uptake are revealing for significant barriers and inequities for CGM use among patients from socially underprivileged communities. This study explores the effect of full subsidies regardless of diabetes type on CGM uptake and HbA1c outcomes in a U.S. adult patient population on Medicaid.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 08,2022

Vida Health’s Spanish-Language Virtual Diabetes Solution Achieves Meaningful Clinical Outcomes

New research published in JMIR Formative Research shows clinically significant Hemoglobin A1C (HbA1C) reduction for a diabetic population who used Vida Health’s Spanish solution. These clinical outcomes reinforce the importance of providing accessible care that’s adapted to fit the needs of diverse populations.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY